This site requires JavaScript to be enabled to work properly. Please modify your settings or use a different browser to continue

      

You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

Thank you, doctor for taking care of your little patients. Together with your colleagues across the globe, you have helped protect over 43 million babies.*,2

Thank you for considering what really matters when choosing a 6-in-1** vaccine.

Safety

Expert Videos


More details

Infanrix Hexa Paediatric What really Matters Real world evidence- Saudi Arabia


More details

*Data on file: 174 million doses/4 = 43.5 million babies vaccinated (divided by 4 as 3+1 is the most conservative schedule available).
**Hexavalent acellular pertussis combination vaccine for prevention against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and diseases caused by Haemophilus influenzae type b
. 1

References:

  1. GlaxoSmithKline Biologicals. Infanrix hexa Summary of Product Characteristics, 2018. 
  2. GlaxoSmithKline DoF: DNG 2019N395506_00 (Number of doses distributed worldwide).

Trade marks are owned by or licensed to the GSK group of companies.
©2021 GSK group of companies or its licensor.